...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Zenith cost basis

fr944

refer to the Resverlogix.com/investors documents/Sedar filings/6/30/13 

RESVERLOGIX CORP. ADJUSTED COST BASE Resverlogix’s estimation of the proportionate allocation of the adjusted cost base of the Resverlogix Common Shares immediately before the share exchange, based on the relative estimated fair market values of the New Resverlogix Common Shares and the Zenith Common Shares immediately after the share exchange, is as follows: Resverlogix New Common Shares 90.9% Zenith Common Shares 9.1% This allocation is not binding on the Canada Revenue Agency or any shareholder. 

Example: You had 10,000 shares of RVX which you purchased for $3.50 per share and held them at the Spinco record dated

               You received 10,000 sares of Zenith

               Your cost basis for RVX is now $31,815($35,000*.909)

               Your cost basis for Xenith is $3,185($35,000*.091)

My trading account still shows 0 value for my Zenith markers

Chicagoest 

Share
New Message
Please login to post a reply